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Measurement and determinants of tuberculosis
outcome in Karonga District, Malawi
J.R. Glynn,' D.K. Warndorff,2 P.E.M. Fine,3 M.M. Munthali,4 W. Sichone,5 &
J.M. P6nnighaus6
Evaluation of disease outcome is central to the assessment of tuberculosis (TB) control programmes. In the
study reported in this article we examined the factors influencing the measurement of outcome, survival rates
during and after treatment, smear conversion rates, and relapse rates for patients diagnosed with TB in a
rural area of Malawi between 1986 and mid-1994.
Patients with less certain diagnoses of TB were more likely to die than those with confirmed TB, both
among those who were seropositive and those who were seronegative to human immunodeficiency virus
(HIV). The mortality rate among smear-positive patients with a separate culture-positive specimen was half
that of patients with no such diagnostic confirmation. Patients not registered by the Ministry of Health had
much higher mortality and default rates than did registered patients. Among smear-positive patients, HIV
serostatus was the most important influence on mortality both during and after treatment (crude hazard ratios
(95% confidence intervals) = 5.6 (3.0-10) and 7.7 (3.4-17), resp.), but HIV serostatus did not influence
smear conversion rates. The initial degree of smear positivity influenced smear conversion rates, but not
mortality rates. No significant predictors of relapse were identified.
Unless considerable care is taken to include all TB patients, and to exclude nontuberculous patients,
recorded TB outcome statistics are difficult to interpret and may be misleading. In populations with high rates
of HIV infection, TB target cure rates of 85% are unrealistic. When new interventions are assessed it cannot
be assumed that factors which influence the smear conversion rate will also influence the mortality rate.
Introduction
Mycobacterium tuberculosis causes around 3 million
deaths a year worldwide, more deaths than are
caused by any other single pathogen. Tuberculosis
(TB) control policies emphasize the importance of
case finding and treatment, particularly of smear-
positive cases, aiming for a "cure" rate of 85% (1). A
high cure rate is seen as the key priority. Incomplete
treatments add to the pool of infectious cases and
increase drug-resistant TB, and it is argued that good
quality treatment services will attract new patients
and lead to increased case detection.
I Lecturer, London School of Hygiene and Tropical Medicine,
Keppel Street, London, WC1 E 7HT, England. Requests for
reprints should be sent to Dr Glynn at this address.
2 Field Director, Karonga Prevention Study, Malawi.
3Professor, London School of Hygiene and Tropical Medicine,
London, England.
4Deceased. Formerly: Senior Leprosy Control Assistant, Karonga
Prevention Study, Malawi.
5Leprosy Control Assistant, Karonga Prevention Study, Malawi.
6 Formerly: Field Director, Karonga Prevention Study, Malawi.
Currently: Dermatologist (Tropical Medicine), Hautklinik Plauen,
Plauen, Germany.
Reprint No. 5862
Measurement of outcome is thus central to TB
control, and outcomes are often reported (2,3). Cure
rates are usually calculated using a cohort approach
based on registered patients (4, 5). If some patients
are not registered, for example, because they die
before or shortly after hospital admission, the
results obtained will be misleading. Outcomes re-
corded may also depend on the diagnostic criteria
used; mortality may be higher among patients
misdiagnosed as having TB than among those cor-
rectly diagnosed and treated. The impact of these
factors on recorded outcomes is largely unknown,
and the data required to define it are not routinely
available. None the less, knowledge of these factors
is essential for assessing TB programme perform-
ance, since the failure to register all diagnosed pa-
tients is likely to lead to over-optimistic reporting
of treatment outcomes, and diagnostic failures
leading to the treatment of patients with other
diseases as TB patients have costs to both patients
and the health service, and could worsen measured
outcomes.
Interpretation of outcome data depends on
knowledge of the characteristics of the patients in-
cluded. Even in the best-run programmes, TB cure
rates of 85% may no longer be possible because of
the high mortality rates experienced by patients
co-infected with human immunodeficiency virus
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(HIV). We present a detailed analysis of factors in-
fluencing outcome among smear-positive TB pa-
tients in a rural area of northern Malawi, considering
survival during treatment and subsequent survival
among those successfully treated, smear conversion
rates, and relapse rates.
Methods
Karonga District is the site of the Lepra Evaluation
Project/Karonga Prevention Study (KPS), a large
epidemiological study of leprosy and TB (6, 7). Dur-
ing the 1980s, the KPS carried out two total popula-
tion surveys in this area, whose current population is
approximately 180000. The second survey formed
the recruitment phase for a vaccine trial of repeat
BCG vaccination and BCG combined with killed
Mycobacterium leprae (7). In the surveys, the popu-
lation was screened for leprosy by physical examina-
tion and for TB by enquiring about any coughs that
had lasted at least one month and by examination for
cervical lymphadenopathy. From 1990 case finding
has included "enhanced passive ascertainment": all
individuals who attended health centres for what-
ever reason and had not been for the previous 12
months were screened for leprosy and TB as in the
surveys. Patients could also self-report with cough or
other symptoms of TB at any time, and the majority
of TB patients were ascertained in this way. Further
suspects were identified among patients already
admitted for other reasons.
TB suspects were asked to produce three spu-
tum specimens, and those with positive microscopy
or culture results were referred to hospital for initial
intensive phase treatment. All TB patients treated in
the hospital were registered by the Ministry of
Health as part of the national TB programme. Irre-
spective of how they were initially identified, all pa-
tients were seen on the ward by KPS staff to establish
contact and identify place of residence because the
KPS was responsible for outpatient care of all TB
cases in the district. Since 1988 all adult patients who
gave their consent have been tested serologically for
infection with HIV using a four-test protocol, as pre-
viously described (8). Sputum specimens were taken
for diagnosis, and for sputum smear-positive patients
after 2 months, 5 months, and at the end of therapy.
Since 1986 all sputum specimens have been ex-
amined by microscopy and cultured at KPS head-
quarters in Chilumba, Malawi. Cultures suggestive
of TB were sent to the PHLS Mycobacterium
Reference Laboratory, in Cardiff, Wales, for species
identification and drug sensitivity testing (9).
Treatment followed Malawi Government
guidelines and was free (10). The current regimens
were started in the district in 1986. Smear-positive
patients received a regimen of streptomycin,
isoniazid, rifampicin, and pyrazinamide for 2 months
in hospital followed by 6 months of isoniazid and
thiacetazone as outpatients. If the sputum smear was
still positive after 2 months, the initial phase was
prolonged, and if follow-up specimens were smear-
positive the patient was readmitted. Smear-negative
patients received the standard regimen of streptomy-
cin, isoniazid, and thiacetazone for 1 month in hospi-
tal, followed by isoniazid and thiacetazone for 11
months as outpatients. Smear-positive patients who
failed or relapsed received a regimen including
ethambutol. A few patients with extrapulmonary TB
diagnosed by KPS were treated as outpatients before
the new regimens were well established.
Patients were included in the present analysis if
they were diagnosed after 1 January 1986 and were
not known to have had previous TB. This date coin-
cided with the establishment of routine culture and
the start of the new treatment regimens. Patients
diagnosed after 30 June 1994 have been excluded to
ensure that outcome data were complete on all pa-
tients. Diagnosis was based on clinical symptoms and
signs, chest X-ray, sputum smear and culture, histol-
ogy of suspect TB skin lesions or lymph nodes, and,
in some children, on tuberculin results. For pulmo-
nary TB, "certain" cases were culture positive on at
least one sputum specimen and had at least one
other specimen positive on culture or microscopy;
"probable" cases were all other patients with posi-
tive sputum microscopy or culture results, except
those with only a single microscopy-positive sputum
with fewer than 10 bacilli per 100 fields; and "pos-
sible" cases were those diagnosed by X-ray and those
with a single positive microscopy result with fewer
than 10 bacilli per 100 fields.
Extrapulmonary cases were "certain" if the
biopsy was classified as confirming TB, or if culture
or microscopy of aspirated fluid (pleural, ascites, or
cerebrospinal fluid) was positive. Clinically diag-
nosed cases of tuberculous lymphadenitis and other
extrapulmonary TB cases for whom the biopsy was
suggestive of TB were classified as "probable". All
other cases registered by the Ministry of Health or
diagnosed only by KPS staff were classified as "pos-
sible". A smear-positive patient was any patient with
a positive smear within 2 months of diagnosis (ex-
cluding those for whom the relevant culture showed
only atypical mycobacteria). The same criteria were
used to classify relapses.
Outpatient follow-up was carried out by KPS
staff, who saw the patients monthly. Patients were
visited at agreed meeting places or in their own
homes; tablets were counted to check compliance,
the patient was asked about any drug reactions, and
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was given the next month's supply of drugs. Follow-
up sputum specimens were taken if appropriate.
Patients with certain or probable TB registered
since January 1988, who were resident in the district
and had been discharged at the end of treatment,
were followed up at yearly intervals. If found, they
were asked about any coughs, and sputum was col-
lected if appropriate. If they were not found, infor-
mation was sought from other household members
or neighbours as to whether they were known to
have died or to have left the district. Patients who
relapsed were identified by the continued monitor-
ing at health centres and the hospital.
Analyses of the determinants of outcome used
survival analysis and Cox's proportional hazards
models. For analyses of outcome of the disease
episode, subjects were "censored" when they were
discharged or lost to follow-up. For longer-term out-
comes subjects were censored when they left the
district or were lost to follow-up. The proportional
hazards assumption was checked by inspection of the
plots and by tests for interaction with time. If
nonproportional hazards were found, stratified mod-
els were used and the effect of the variable was as-
sessed for different time periods, defined using the
median time to the outcome of interest (the median
event time). These analyses were restricted to
"certain" or "probable" smear-positive cases who
received the correct short-course therapy.
The risk factors considered are shown in Table
4. The degree of smear positivity was taken as the
maximum observed within the first 2 months, re-
corded in four categories, ranging from 1-9 acid-fast
bacilli (afb) per 100 fields to 10-99 afb per field. Drug
resistance was recorded if results were available on a
specimen taken within 1 month of the start of treat-
ment. BCG status was assessed on the basis of scars
(11) and vaccination records from the 1980s repeat
BCG trial or childhood vaccinations. Since the char-
acteristics of patients who were not in the trial may
differ from those who were included (e.g. recent im-
migrants to the district were not part of the trial
population), patients who neither took part nor re-
fused to take part in the trial were also considered
separately in the analyses of the effect of BCG on
outcome.
The rate of sputum smear conversion was also
studied. The date of conversion was taken as the
midpoint of the interval between the last positive
and the first subsequent negative microscopy result.
This should be a reasonable approximation if the
interval is short, but is likely to be inaccurate for
patients who fail to have specimens taken between
diagnosis and the end of therapy. The analysis was
therefore re-run, excluding patients for whom the
interval was >3 months. If there was no negative
specimen after one or more positive specimens, the
record was censored at the time of the last positive
specimen.
For estimating the effect of diagnostic certainty
on outcome, the crude figures are potentially mis-
leading since patients who survive longer have more
chance of having their TB confirmed. Therefore, for
these analyses the certainty groups were based only
on data available within the first 2 months, and the
outcome beyond 2 months was analysed.
Results
Information was available on 1655 certain, probable
or possible TB patients who were either registered
by the Ministry of Health as TB cases (1524), or
diagnosed only by KPS staff (131 (8%)). Patients
failed to be registered because they were treated as
outpatients (10 patients), died (82), defaulted (38),
or for unknown reasons (1). Overall, 22.5% of the
patients died before the end of treatment, 57.9%
reached the end of treatment and were discharged,
4.3% were transferred out of the district, and the
remaining 15.3% defaulted and were lost to follow-
up. Of the deaths, 23% occurred among the 8% of
patients who were not registered by the Ministry of
Health. Excluding individuals who were not regis-
tered, the case fatality rate (defined as death before
the completion of treatment) was 19.0%, 62.4%
were discharged, 4.7% were transferred, and 14.0%
were lost to follow-up.
Overall case fatality
Case fatality rates were similar in those classified as
pulmonary and extrapulmonary, but were lower
among those with confirmed TB. The trend in mor-
tality rates with diagnostic certainty was evident
among those surviving beyond 2 months (X2 test for
trend = 22; P < 0.001) (Table 1) and persisted after
stratifying for HIV (Table 2). Since type of disease
and treatment both influence outcome, further
analysis of the effect of certainty of diagnosis on
mortality beyond 2 months was restricted to smear-
positive patients who received short-course therapy
(Fig. 1). Compared to certain cases, probable
and possible cases had higher mortality rates:
hazard ratios of 2.0 (95% confidence interval (CI) =
1.1-3.9) and 4.2 (95% CI = 2.0-8.7), respectively.
This effect was unchanged by controlling for possible
confounders (age, sex, HIV serostatus, year of diag-
nosis, degree of smear positivity, and BCG status) in
a Cox's regression analysis.
Overall, 35% of HIV-positive patients died be-
fore the end of treatment, compared with 11% of
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Table 1: Outcome among TB patients who survived the first 2 months, by type of disease and certainty of
diagnosis, Karonga District, Malawi, 1986-94
Pulmonary TB Extrapulmonary TB Unknown
Certaina Probablea Possiblea Certaina Probablea Possiblea Possiblea
No. discharged 268 (78.4)b 228 (72.8) 229 (66.0) 34 (77.3) 16 (59.3) 139 (69.2) 44 (67.7)
No. transferred 14 (4.1) 13 (4.2) 14 (4.0) 1 (2.3) 0 (0.0) 6 (3.0) 0 (0.0)
No. lost 33 (9.7) 24 (7.7) 32 (9.2) 4 (9.1) 8 (29.6) 23 (11.4) 8 (12.3)
No. died 27 (7.9) 48 (15.3) 72 (20.7) 5 (11.4) 3 (11.1) 33 (16.4) 13 (20.0)
Total 342 313 347 44 27 201 65
a Diagnostic groups were defined on the basis of data available within the first 2 months.
b Figures in parentheses are percentages.
Table 2: Outcome, by human immodeficiency virus (HIV) serostatus and certainty of diagnosis, among TB
patients who survived the first 2 months, Karonga District, Malawi, 1986-94
HIV positive: HIV negative: Unknown HIV status:
Certaina Probablea Possiblea Certaina Probablea Possiblea Certaina Probablea Possiblea
No. 61 (57.0)b 46 (51.7) 69 (49.9) 183 (88.4) 119 (85.0) 134 (74.0) 58 (80.6) 79 (71.2) 209 (71.6)
discharged
No. 8 (7.5) 5 (5.6) 6 (4.3) 5 (2.4) 2 (1.4) 5 (2.8) 2 (2.8) 6 (5.4) 9 (3.1)
transferred
No. lost 17 (15.9) 9 (10.1) 14 (10.0) 13 (6.3) 12 (8.6) 18 (9.9) 7 (9.7) 11 (9.9) 31 (10.6)
No. died 21 (19.6) 29 (32.5) 51 (36.4) 6 (2.9) 7 (5.0) 24 (13.3) 5 (6.9) 15 (13.5) 43 (14.7)
Total 107 89 140 207 140 181 72 i11 292
a Defined on the basis of data available within the first 2 months.
b Figures in parentheses are percentages.
Fig. 1. Kaplan-Meier plot of the influence of diagnos-
tic certainty group on mortality of smear-positive TB
patients who received short-course therapy and sur-
vived at least 2 months. The diagnostic groups were
based on data available within the first 2 months.
Shown also is the number of people still being followed up
in each category.
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HIV-negative patients and 25% of those whose HIV
serostatus was unknown. Among those with un-
known HIV serostatus, 235 were aged > 14 years
and were diagnosed after 1988 and so should have
been tested if their consent had been given. The
reason for the lack of testing was not recorded, but
111 of such patients died, transferred, or were lost to
follow-up within the first 3 months.
Smear-positive patients
The main analysis of risk factors for outcome was
restricted to smear-positive patients. In total, 682
patients were smear positive, of whom 642 were reg-
istered. Of the registered patients, 591 received the
correct short-course therapy, 20 the standard regi-
men, and two the retreatment regimen. All but one
of the unregistered patients received no treatment.
The treatment received by the other patients is not
known. The outcomes for smear-positive patients
0o 350 are shown in Table 3. Overall, 16.0% died before the
end of treatment, 13.1% of those registered by the
WHO 98070 Ministry of Health, and 62.5% of those not regis-
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tered. A total of 64.2% completed treatment, of
whom 91% were cured as indicated by two negative
smears including one at the end of treatment.
However, five of the patients classified as cured on
the basis of smears, and one classified as "putative
cure" (Table 3) had positive cultures at the end of
treatment.
Mortaity among certain and probable
smear-positive patients receiving short
course therapy
Of the certain or probable smear-positive patients,
527 received short-course therapy and were included
in the survival analyses (Table 4). In the crude analy-
sis, mortality rates were higher among HIV positives
(Fig. 2), among those without evidence of BCG vac-
cination, among older patients, and in more recent
years. The mortality rate for HIV-positive patients
was 42 per 100 person-years at risk (pyar) (95% CI =
29-59), and for HIV-negative patients 7.6/100 pyar
(95% CI = 4.6-12.6).
After controlling for age, the effect of HIV
serostatus on mortality was increased, and that of
BCG vaccination status was decreased (Table 5).
After controlling for HIV serostatus, the effect of
age became significant (Table 5) and that of year
of diagnosis was lost (hazard ratio = 1.0; 95% CI =
0.9-1.2). There was no other confounding and no
statistically significant interactions between the risk
factors examined. However, the apparent reduction
in mortality associated with BCG was seen primarily
among HIV-positive patients. After controlling
for age, comparison of those who had not been
Table 3: Distribution of outcomes
Karonga District, Malawi, 1986-94
BCG vaccinated to those who had, the hazard ratio
of dying was 3.4 (95% CI = 1.5-7.8) among HIV
positives, and 1.5 (95% CI = 0.5-4.5) among HIV
negatives.
A total of 208 patients were not included in the
1980s repeat BCG vaccine trial. Among these
patients, 2/53 of those with BCG scars and 20/86 of
those without such scars died (hazard ratio = 6.5;
95% CI = 1.5-27.6). After controlling for age and
HIV serostatus, those without BCG scars still
Fig. 2. Kaplan-Meier plot of influence of HIV
serostatus on death during treatment for "certain"
and "probable" smear-positive TB patients who re-
ceived short-course therapy, Karonga District, Malawi
1986-94. Shown also are the number of people still being
followed up in each category.
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among smear-positive TB patients,
Ministry of Health Not Ministry of Health
Outcomea registered registered Total
Cure 397 (61.8)b 0 397 (58.2)
Putative cure 34 (5.3) 0 34 (5.0)
Treatment
completed 7 (1.1) 0 7 (1.0)
Failure 23 (3.6) 0 23 (3.1)
Transferred 38 (5.9) 0 38 (5.6)
Lost 59 (9.2) 15 (37.5) 74 (10.9)
Died 84 (13.1) 25 (62.5) 109 (16.0)
Total 642 40 682
a Cure implies negative smears on at least two occasions, including one at the end of
treatment. Putative cure implies one negative smear at the end of treatment or at least two
negative smears after the last positive smear, but none at the end of treatment. Treatment
completed implies discharged from treatment apparently cured but not fulfilling the other
criteria. Failure implies the patient became smear positive again at least 5 months after
starting treatment (two of these patients subsequently died and three were lost to follow-up).
b Figures in parentheses are percentages.
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Table 4: Associations between various risk factors and outcome of smear-positive TB among "certain" and
"probable" TB patients who received short-course therapy, Karonga District, Malawi, 1986-94
Death during treatment: Sputum smear conversion:
No. of
Risk factor patients Hazard ratioa P-valueb Hazard ratioa P-valueb
Age (years)
< 30 181 (13)C 1 1
31-45 171 (22) 1.82; 0.93-3.57d 0.08 0.87; 0.70-1.07 0.2
>45 175 (17) 1.24; 0.61-2.51 0.6 0.69; 0.56-0.85 0.001
Sex
Female 238 (21) 1 1
Male 289 (32) 1.30; 0.75-2.26 0.3 0.85; 0.71-1.02 0.08
HIV serostatus
Negative 281 (15) 1 1
Positive 134 (32) 5.59; 3.02-10.4 <0.001 1.23; 0.99-1.52 0.07
Degree of smear positivity:
1-9 afb/1 00 fields 50 (4) 1 1
1-9afb/10 fields 209 (23) 1.48; 0.51-4.28 0.99; 0.72-1.35e
1-9afb/field 149 (17) 1.43; 0.48-4.28 0.72; 0.52-0.99e
l10afb/field 109 (9) 0.97; 0.30-3.14 0.6 0.63; 0.45-0.88e <0.001
Drug resistance:
None 342 (27) 1 1
1 drug 29 (3) 1.30; 0.40-4.30 1.10; 0.74-1.62
-2 drugs 12 (2) 2.18; 0.52-9.17 0.3 0.79; 0.42-1.48 0.7
Year of diagnosis 527 (53) 1.22; 1.08-1.39 0.001 0.99; 0.96-1.03 0.7
BCG status
Positive 306 (22) 1 1
Doubtful 20 (2) 1.52; 0.36-6.47 0.6 0.93; 0.59-1.48 0.8
Negative 139 (21) 2.26; 1.24-4.11 0.008 1.01; 0.82-1.24 1.0
a Results are not adjusted for any confounders.
b Except for BCG status and age, P-values quoted are for linear trend across the groups.
c Figures in parentheses are number of deaths.
d Figures in italics are the 95% confidence intervals.
e Nonproportional hazards, see text for details.
Table 5: Hazard ratios for death during treatment among "certain" and "probable" smear-positive TB patients who
received short-course therapy, Karonga District, Malawi, 1986-94
Hazard ratio:
Crude, but limited to
377 patients with
Risk factor n Crude Controlled for age data for all three risk factors Controlled for each other
HIV serostatus
Negative 281 1 1 1 1
Positive 134 5.59; 3.02-10.4a 6.65; 3.48-12.7 5.30; 2.75-10.2 6.30; 3.18-12.5
Age (years)
>30 181 1 1 1
31-45 171 1.82; 0.93-3.57 2.27; 0.99-5.23 2.64; 1.12-6.23
>45 175 1.24; 0.61-2.51 1.48; 0.62-3.52 2.49; 0.99-6.27
BCG status
Positive 306 1 1 1 1
Doubfful 20 1.52; 0.36-6.47 1.33; 0.31-5.72 1.97; 0.46-8.49 1.95; 0.44-8.56
Negative 139 2.26; 1.24-4.11 1.98; 1.08-3.65 2.90; 1.53-5.48 2.53; 1.34-4.80
a Figures in italics are the 95% confidence intervals.
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had higher mortality rates (hazard ratio = 8.6; 95%
CI = 1.8-40.9).
Smear conversion among patients receiving
short-course therapy
The rate of sputum smear conversion depended on
the initial degree of smear positivity, being slower
among individuals with large loads of bacilli (Fig. 3).
It was also slower in older patients and was weakly
associated with sex and HIV status (Table 4). The
results were similar after excluding the 86 patients
who had an interval of >3 months between the last
positive and first negative specimen.
Since the hazard functions for the effect of
degree of smear positivity on smear conversion were
not proportional the multivariate analysis was strati-
fied for smear positivity. The effects of sex and HIV
serostatus were lost after controlling for age and
smear positivity. The effect of age was not altered by
stratifying for smear positivity, and there was no
other confounding.
To assess the effect of degree of smear positivity
without violating the proportional hazards assump-
tion of Cox's survival analysis, we used different time
periods. Half the smear conversions occurred within
the first 35 days, but within this period the hazards
for the effect of degree of smear positivity were still
nonproportional. The period was therefore divided
again using the median event time. Within the first 25
days the hazards were proportional and the degree
of smear positivity was very strongly (negatively)
associated with smear conversion (hazard ratio =
Fig. 3. Kaplan-Meier plot of sputum smear conver-
sion, by degree of smear positivity, among "certain"
and "probable" smear-positive TB patients who re-
ceived short-course therapy, Karonga District, Malawi
1986-94 (afb - acid-fast bacilli).
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E 0.50.
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0
c)- 0.25L
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0.6; 95% CI = 0.4-0.7) for each 10-fold increase
in smear positivity). Beyond 25 days the hazards
were again proportional and the degree of smear
positivity had only a slight effect: hazard ratio = 0.9
(95% CI = 0.8-1.0). These estimates were little
altered by controlling for possible confounders.
Outcome beyond the end of treatment
A total of 431 patients with certain or probable TB
who were discharged at the end of therapy were
actively sought in the follow-up. Further information
was available on 322 (75%) patients -78% of those
who were HIV seronegative and 64% of those who
were HIV seropositive at diagnosis. The median
follow-up time was 2.3 years (10th centile: 9 months;
90th centile: 4.4 years). Follow-up was similar for
males and females and in different age groups. The
major influence on subsequent mortality was HIV
status: 13/207 (6.3%) HIV-negative patients and
20/61 (33%) HIV-positive patients were known to
have died within 2 years.
Detailed analysis of outcome beyond the end of
treatment was restricted to certain or probable TB
patients who had had smear-positive disease treated
with short-course therapy and who had been shown
to have become smear negative (cure and putative
cure in Table 3). Four patients who were culture
positive at the end of treatment were also excluded.
A total of 291 patients fulfilled these criteria, 204
(70%) of whom had information available from the
follow-up period.
The same possible risk factors were considered
as for outcome during treatment (Table 4). In the
univariate analysis only HIV serostatus and year of
diagnosis influenced the mortality rate (Table 6).
Mortality rates for HIV-positive patients were
22/100 pyar (95% Cl = 13-38) and for HIV-negative
patients 2.9/100 pyar (95% Cl = 1.6-5.2). After con-
trolling for HIV status an effect of age became
apparent. There was no statistically significant inter-
action between the factors, but the effect of year of
diagnosis on the mortality rate only occurred among
the HIV-positive patients (Fig. 4, hazard ratio = 1.7;
95% CI = 1.1-2.7) and not among the HIV-negative
patients (hazard ratio = 1.2; 95% CI = 0.7-2.0, after
controlling for age).
Relapses that were classified as certain or prob-
able occurred for 11 of the 204 previously cured
smear-positive patients. Four patients with possible
relapses were excluded. None of the potential risk
factors was associated significantly with relapse
either in the crude analysis or after adjusting for
confounders. Relapses occurred in 2/32 (6.3%) HIV-
positive patients and 6/144 (4.2%) HIV-negative
patients (hazard ratio = 2.62; 95% CI = 0.52-13.1).
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Table 6: Hazard ratios for death after discharge from treatment among
"certain" and "probable" smear-positive TB patients who received short-
course therapy and were shown to be smear-negative, Karonga District,
Malawi, 1986-94
Hazard ratio:
Risk factor n Crude Controlled for each other
HIV serostatus
Negative 145 (11)a 1 1
Positive 34 (14) 7.66; 3.44-17.1b 9.38; 3.89-22.6
Age (years)
s30 69(10) 1 1
31-45 60 (5) 0.65; 0.22-1.90 0.97; 0.31-3.02
>45 75 (15) 1.68; 0.75-3.77 2.73; 1.03-7.18
Year of diagnosis 204 (30) 1.41; 1.09-1.83 1.55; 1.14-2.11
a Figures in parentheses are the number of deaths.
b Figures in italics are the 95% confidence intervals.
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Discussion
In judging the success of a TB control F
much emphasis is placed on the outco
diagnosed cases, particularly the cure r
smear-positive patients. If patients are n(
in the statistics because they die or defaul
results obtained will be over-optimistic
been able to quantify this bias in Karon}
:e of HIV When patients who failed to be registered were
ival beyond included, the main change was in the case fatality
"probable" rate, the true rate among diagnosed smear-positive
hort-course patients being 16%, rather than the 13% recorded
e mbeereof among registered patients. The proportion of de-ip is shown. faulters increased from 9% to 11%, and the propor-tion discharged at the end of treatment fell from
HIV negative 72% to 68% (Table 3). The proven cure rate was low
1988 90(n=88) compared with results from the 1980s in Malawi (10),
but was consistent with more recent data (2).
HIV negative Another important influence on recorded out-
1991 94
(n=57) come is the definition used for a TB case. Patients
with less definite diagnoses had higher mortality
HIV positive rates (Table 1). The difference between the certain
1988-90(n=12) and probable smear-positive patients is particularly
striking since both groups would normally be consid-
HIV positive ered to have strong evidence of TB, and this differ-
1991 94(n=22) ence did not result from confounding by HIV
serostatus or other factors. The higher mortality with
less certain diagnoses is presumably due to inclusion
,-, of some patients who have severe illnesses other
30 35 than TB for which they received inappropriate or
nent inadequate treatment. This may be generally true. In
WHO 98072 two national samples of TB patients in Kenya in the
1960s and 1970s, mortality was lower among indi-
viduals with positive cultures than among those with
negative cultures or who failed to produce sputum
specimens (12, 13).
The major determinant of mortality among TB
,rogramme patients in Karonga District in recent years, both
me among during and after treatment, has been HIV serostatus.
ate among The hazard ratio of 6 among smear-positive patients
ot included for death during treatment is consistent with results
It early, the from elsewhere in Africa (14-17). It has previously
. We have been shown that the mortality rate depends on the
ga District. severity of the immune deficiency (17) and that
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many of the excess deaths are not directly attribut-
able to TB (15, 16). We had no information on the
cause of death in our study.
The mortality rate increased over the years of
this study. After controlling for HIV serostatus, the
effect of year of diagnosis on death during treatment
disappeared, but the mortality rate after the end of
treatment increased 1.4 times each year (Table 6).
This effect was seen principally among the HIV-
positive patients and is likely to reflect the growing
proportion of patients with more advanced HIV
disease later in the epidemic.
The association between BCG vaccination and
mortality of smear-positive patients was surprising.
A study in Kenya found no effect of BCG vaccina-
tion on 6-month mortality (15). In Karonga District,
BCG vaccination does not protect against pulmo-
nary TB (18, 19). In the vaccine trial carried out in
this population in the 1980s all participants without
BCG scars received BCG vaccine (7), so the group of
patients without BCG includes a high proportion of
recent immigrants to the district who may differ in
other ways from the other patients. Excluding trial
participants removes this bias, but there may still be
many differences between those who had been and
those had not been BCG vaccinated. For example, in
this population individuals without BCG scars were
less likely to have had any schooling (11). We had
information on schooling and housing conditions in
the early 1980s for 57% of the smear-positive pa-
tients. Controlling for these factors had no influence
on the effect of BCG vaccination (results not shown)
but they may not closely reflect current socioeco-
nomic conditions. In the repeat BCG trial, the case
fatality rate among previously scar-positive patients
was 13/54 (24%) for those who had received a sec-
ond dose of BCG vaccine and 4/47 (8.5%) among
those who received placebo, corresponding to a rela-
tive risk of 1.8 (95% CI = 0.7-4.5) after stratifying
for HIV status (Karonga Prevention Trial, unpub-
lished results). These results, which go in the oppo-
site direction, make it very unlikely that BCG
vaccination has a protective effect.
Although HIV serostatus and BCG status were
both associated with mortality among smear-positive
patients, they had no effect on the rate of smear
conversion. An influence of HIV on early mortality
but not smear conversion rates has also been re-
ported in Zaire (20). Conversely, the initial degree of
smear positivity strongly influenced smear conver-
sion rates but had no effect on mortality. Smear con-
version rates are used as early indicators of TB
programme performance and as outcome indicators
in treatment trials. Although successful smear con-
version is encouraging, our results suggest that cau-
tion is needed in using smear conversion rates as a
proxy for longer-term successful treatment results.
The faster rate of smear conversion among those
with fewer bacilli makes biogical sense and has been
shown before (21), but this may in part reflect the
greater sampling variability and difficulty in detect-
ing bacilli when they are present in small numbers, so
that repeat specimens may be reported as negative.
In so far as degree of smear positivity is a correlate of
severity of disease, it is surprising that it appeared to
have no influence on mortality.
Compared with older patients younger patients
had faster smear conversion and lower mortality
rates both during treatment and in the subsequent
follow-up. This is consistent with previously pub-
lished findings (15, 16). The lack of a statistically
significant effect of initial drug resistance on either
the smear conversion rate or the mortality rate is
probably due to the small numbers of patients with
multiple drug resistance in this series.
Other studies have found higher rates of relapse
among HIV-positive patients than we have reported
here (22, 23), but our sample size was small (only 23
HIV-positive patients still being followed up 1 year
after discharge) and the confidence intervals are cor-
respondingly wide. In Karonga the relapse rate for
HIV-positive patients was 3.6/100 pyar (95% CI =
0.9-15) and for HIV-negative patients 1.6/100 pyar
(95% CI = 0.7-3.5). In Nairobi equivalent rates for
relapses were 16.7/100 pyar (estimated 95% CI =
8.0-31) and 0.5/100 pyar (estimated 95% CI = 0.01-
2.8) (22); in Lusaka 22/100 pyar (95% CI = 13-36)
and 6/100 pyar (95% CI = 1-17) (23); and in Kin-
shasa 23/100 pyar (95% CI = 9.4-48) and 4.4/100
pyar (95% CI = 1.9-8.8). In Nairobi recurrence was
confirmed by two positive cultures; in Lusaka, bacte-
riologically or histologically in 11/16 HIV-positive
cases and 2/3 HIV-negative cases; and in Kinshasa all
relapses were smear positive. In Kinshasa, as in
Karonga, relapses were only counted for patients
who had had previous negative sputum smears and
culture. These differences may have arisen because
some recurrences are due to new infections, and the
chance of these occurring is likely to be greater in
large cities than in Karonga, which is a rural district.
Our study has shown that some patients, par-
ticularly those with worse outcomes, are missed by
the usual processes of registration. To some extent
this is inevitable and the magnitude of this bias is
likely to vary from place to place and over time. The
8% of patients missed in Karonga District had a
small effect on the overall results, but random checks
in urban areas of Malawi have found that 10-25% of
patients recorded as smear positive in the laboratory
register were not entered in the Ministry of Health
register (A. Harries, personal communication, 1996)
(24). It is important that TB control officers appreci-
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ate the need to evaluate outcome on all TB patients,
and that the incentives to provide "good" outcome
statistics do not override the need for accuracy.
Methods should be found to collate diagnostic
"cough" or laboratory registers with treatment regis-
ters in order to identify missing patients. Diagnosed,
rather than treated, patients should be the denomi-
nator for official statistics. The striking influence
of diagnostic certainty group on outcome also makes
it difficult to compare results in different places
and at different times unless rigorous criteria are
used.
In Karonga District, 23% of HIV-positive cer-
tain and probable smear-positive patients who re-
ceived short-course therapy died during treatment.
Similarly high risks have been found elsewhere (14-
16). With case fatality rates of this magnitude and
increasing proportions of HIV-positive subjects
among TB patients (currently >50% in Karonga
District) it will be impossible for control pro-
grammes to achieve cure rates of 85%. The in-
creased post-treatment mortality of HIV-infected
patients in more recent years demonstrates the
changing epidemiology of HIV as the epidemic un-
folds and the need for continued monitoring of its
effects.
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Resume
Mesure et determinants de l'issue de la
tuberculose dans le district de Karonga,
Malawi
L'6valuation de l'issue des infections tuberculeuses
est la pierre angulaire de toute evaluation des pro-
grammes de lutte contre la tuberculose, car les
resultats peuvent en etre fauss6s si des malades
dont la tuberculose n'est pas av6ree sont inclus
dans les statistiques officielles ou si ceux qui
d6cedent ou qui sont rapidement perdus de vue
sont exclus. Le present article examine, dans une
r6gion rurale du nord du Malawi, les facteurs qui
influencent la mesure de l'issue, les taux de survie
pendant et apres le traitement, les taux de
n6gativation des frottis et les taux de rechute.
Les donnees concernant 1655 malades chez
qui la tuberculose a ete diagnostiquee dans le dis-
trict de Karonga, Malawi, entre 1986 et mi-1994, y
compris 682 cas a frottis positif, ont pu etre
analys6es. Un sous-groupe de patients a 6te
activement suivi apres la fin du traitement. Une
analyse des courbes de survie a ete faite pour
etudier les facteurs qui influencent les diverses
issues de la maladie.
Les malades dont le diagnostic de tuberculose
6tait douteux avaient une plus forte probabilit6 de
deceder que ceux dont la tuberculose 6tait
confirm6e, et cet effet etait observ6 aussi bien
chez les patients positifs pour le virus de
l'immunod6ficience humaine (VIH) que chez les
patients VlH-negatifs. Parmi les malades a frottis
positif, ceux qui avaient en outre un pr6levement
positif apres culture avaient une mortalit6 moitie
moindre que les autres. Chez les malades non
enregistres par le Ministere de la Sant6 (8% du
total) les taux de mortalite et d'abandon etaient
beaucoup plus 6leves que chez les malades
enregistres: parmi les malades a frottis positif, 23%
des d6ces sont survenus chez ceux qui n'6taient
pas enregistr6s. Chez les malades a frottis positifs
dont le diagnostic etait "certain" ou "probable" et qui
ont commence un traitement de courte dur6e, le
facteur ayant le plus d'influence sur la mortalit6
pendant et apres le traitement 6tait le statut
s6rologique vis-a-vis du VIH (rapports de risque
bruts et intervalles de confiance a 95%: 5,6 (3,0-10)
et 7,7 (3,4-17) respectivement), mais ce facteur
n'avait pas d'influence sur les taux de n6gativation
des frottis. Pour ces derniers, le facteur principal
etait le degr6 de positivit6 des frottis au moment du
diagnostic, mais ce facteur etait sans influence sur
la mortalit6. Aucun facteur predictif significatif n'a
e trouve pour les taux de rechute.
Si l'on ne veille pas de facon tres attentive au
recensement de tous les malades atteints de
tuberculose et a 1'exclusion des malades non
tuberculeux, les statistiques sur l'issue de la
tuberculose sont difficiles a interpr6ter et peuvent
induire en erreur. Dans les populations ou le taux
d'infection par le VIH est 61ev6, des taux de
gu6rison cibles de 85% sont irr6alistes. Lors de
l'evaluation de nouvelles interventions il n'est pas
possible de supposer que les facteurs qui
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influencent les taux de negativation des frottis
influenceront 6galement les taux de mortalite.
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